Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | PHGDH | O43175 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.57 |
| ▸ | CCR2 | P41597 | 4/20 | 0.55 |
| ▸ | AHR | P35869 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3500225 | 0.87 | KDM4E (0.59) | KDM4EALDH1A1HPGDHSD17B10MCL1 | |
| SCHEMBL31623400 | 0.86 | MCL1 (0.62) | KDM4EALDH1A1HPGDHSD17B10MCL1 | |
| SCHEMBL2828847 | 0.86 | MCL1 (0.62) | KDM4EALDH1A1HPGDHSD17B10MCL1 | |
| SCHEMBL31623397 | 0.86 | MCL1 (0.62) | KDM4EALDH1A1HPGDHSD17B10MCL1 | |
| SCHEMBL17324809 | 0.86 | RXFP1 (0.64) | KDM4EALDH1A1HPGDHSD17B10MCL1 | |
| SCHEMBL13415456 | 0.85 | RXFP1 (0.62) | KDM4EALDH1A1HPGDHSD17B10MCL1 | |
| SCHEMBL2643465 | 0.83 | RXFP1 (0.60) | KDM4EALDH1A1HPGDHSD17B10MCL1 | |
| SCHEMBL24198804 | 0.82 | RXFP1 (0.59) | KDM4EALDH1A1HPGDHSD17B10MCL1 | |
| SCHEMBL17321377 | 0.82 | RXFP1 (0.59) | KDM4EALDH1A1HPGDHSD17B10MCL1 | |
| SCHEMBL4919697 | 0.82 | L3MBTL1 (0.70) | KDM4EALDH1A1HPGDHSD17B10RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108350034-B | Antimicrobial polymyxin derived compounds | 莫纳什大学 | 2022-03-11 | — | — | CN | claimed |
| CN-115850241-B | Substituted heterocyclic compound containing alpha-ketone skeleton and application thereof | 中国药科大学 | 2025-01-14 | — | — | CN | disclosed |
| US-20240391901-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND CONTAINING ALPHA-KETONE FRAMEWORK, AND USE THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2024-11-28 | — | — | US | disclosed |
| CN-114702504-B | Trifluoromethyl substituted indolopyranone compound, preparation method thereof and application thereof in antitumor drugs | 平顶山学院 | 2023-04-07 | — | — | CN | disclosed |
| WO-2023046055-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND CONTAINING α-KETONE FRAMEWORK, AND USE THEREOF | 中国药科大学 | 2023-03-30 | — | — | WO | disclosed |
| CN-115850241-A | Substituted heterocyclic compound containing alpha-ketone skeleton and application thereof | 中国药科大学 | 2023-03-28 | — | — | CN | disclosed |
| CN-114702504-A | Trifluoromethyl substituted indolopyranone compound, preparation method thereof and application thereof in antitumor drugs | 平顶山学院 | 2022-07-05 | — | — | CN | disclosed |
| US-11304929-B2 | Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-04-19 | — | — | US | disclosed |
| CN-108350034-B | Antimicrobial polymyxin derived compounds | 莫纳什大学 | 2022-03-11 | — | — | CN | disclosed |
| US-20220008386-A1 | TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-01-13 | — | — | US | disclosed |
| CN-1134440-C | 4-oxo-3,5-dihydro-4H-pyridazino [4,5-b]-indole-1-acetamide derivatives, their prepn. and their application in therapy | �����ʩ���عɷݹ�˾ | 2004-01-14 | — | — | CN | disclosed |
| EP-1001935-B1 | INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2003-10-08 | — | — | EP | disclosed |
| EP-1000063-B1 | 4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b]INDOLE-1-ACETAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI SYNTHELABO (FR) | 2002-10-23 | — | — | EP | disclosed |
| EP-0934319-B1 | 1H-PYRIDO[3,4-b]INDOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI SYNTHELABO (FR) | 2002-06-05 | — | — | EP | disclosed |
| US-6288103-B1 | MONOCYTE CHEMOATTRACTANT PROTEINS ANTAGONIST SUCH AS N-(3-CHLOROPHENYLSULPHONYL)INDOLE-2-CARBOXYLIC ACID; ANTIINFLAMMATORY AGENTS | ZENECA LIMITED (GB) | 2001-09-11 | — | — | US | disclosed |
| CN-1265108-A | 4-oxo-3,5-dihydro-4H-pyridazino [4,5-b]-indole-1-acetamide derivatives, their prepn. and their application in therapy | SANOFI SYNTHELABO (FR) | 2000-08-30 | — | — | CN | disclosed |
| EP-1001935-A1 | INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS | ZENECA LIMITED (GB) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999007678-A1 | INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS | ZENECA LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
| US-5852046-A | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-12-22 | — | — | US | disclosed |
| EP-0639573-A1 | Benzocondensed five membered heterocycles, process of their preparation, their use as drug, as diagnostic means and pharmaceuticals containing it | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11304929-B2 | Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors | PHGDH, G6PD, PHPT1 | KDM4E 2891/4885ALDH1A1 168/4885HPGD 63/4885 |
| US-20240391901-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND CONTAINING ALPHA-KETONE FRAMEWORK, AND USE THEREOF | FAAH, FAAH2, FAH | KDM4E 1478/4885ALDH1A1 427/4885HPGD 528/4885 |
| US-20220008386-A1 | TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS | PHGDH, G6PD, PHPT1 | KDM4E 2891/4885ALDH1A1 168/4885HPGD 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.